Title:
ANTI-HEPATITIS B VIRUS AGENT
Document Type and Number:
WIPO Patent Application WO/2018/043747
Kind Code:
A1
Abstract:
Provided is an anti-hepatitis B virus drug which comprises a compound having a specific structure or a salt thereof and can exhibit an interferon-like activity.
Inventors:
KAKEYA HIDEAKI (JP)
TAKAHASHI NOBUAKI (JP)
HAYASHI KYOHEI (JP)
KOJIMA SOICHI (JP)
FURUTANI YUTAKA (JP)
TAKAHASHI NOBUAKI (JP)
HAYASHI KYOHEI (JP)
KOJIMA SOICHI (JP)
FURUTANI YUTAKA (JP)
Application Number:
PCT/JP2017/031825
Publication Date:
March 08, 2018
Filing Date:
September 04, 2017
Export Citation:
Assignee:
UNIV KYOTO (JP)
International Classes:
A61K31/4375; A61K31/444; A61K31/4545; A61K45/00; A61P1/16; A61P31/20; A61P43/00
Foreign References:
| JP2014532626A | 2014-12-08 |
Other References:
KONISHI,HIDEYUKI ET AL.: "An orally available, small-molecule interferon inhibitis viral replication.", SCIENTIFIC REPORTS, vol. 2, 2012, XP055472204
HUAN,WANG ET AL.: "Discovery of Imidazol[1,2-a] [1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor.", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 9, 2015, pages 977 - 981, XP055472205
HUAN,WANG ET AL.: "Discovery of Imidazol[1,2-a] [1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor.", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 9, 2015, pages 977 - 981, XP055472205
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: